GKL-006 clinical trials
Also written GKL-006.
How each study uses GKL-006 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the GKL-006 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 3
Beijing Gene Key Life Technology Co., Ltd (4) · Beijing YouAn Hospital (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test GKL-006.
- Nov 2026A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaPhase 1 · Beijing Gene Key Life Technology Co., Ltd
- Mar 2027A Study of GKL-006 Injection in Patients With Advanced Pancreatic CancerPhase 1/2 · Beijing Gene Key Life Technology Co., Ltd
- Sep 2027GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaPhase 2 · Beijing Gene Key Life Technology Co., Ltd
Studies
Open first, then newest update. How each study uses GKL-006 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of GKL-006 Injection in Patients With Advanced Pancreatic CancerRecruitingPhase 1/2Beijing Gene Key Life Technology Co., LtdNCT07777211Written as GKL-006 injection
- GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular CarcinomaRecruitingPhase 2Beijing Gene Key Life Technology Co., LtdNCT07209813Written as GKL-006 Injection
- Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor TherapyRecruitingPhase 2Beijing YouAn HospitalNCT05962450Written as iNKT Cells
- Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular CarcinomaCompletedPhase 1Beijing Gene Key Life Technology Co., LtdNCT07845266Written as GKL-006 Injection
- A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular CarcinomaActive, not recruitingPhase 1Beijing Gene Key Life Technology Co., LtdNCT07713290Written as GKL-006 Injection
- Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCCCompletedPhase 2Beijing YouAn HospitalNCT04011033Written as iNKT cells
- Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCCCompletedPhase 1Beijing YouAn HospitalNCT03175679Written as iNKT cells